tradingkey.logo

Insight Molecular Diagnostics Inc <IMDX.OQ> expected to post a loss of 23 cents a share - Earnings Preview

ReutersAug 8, 2025 9:35 PM
  • Insight Molecular Diagnostics Inc IMDX.OQ IMDX.O is expected to show a rise in quarterly revenue when it reports results on August 11 for the period ending June 30 2025

  • The Nashville Tennessee-based company is expected to report a 180.8% increase in revenue to $292 thousand from $104 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Insight Molecular Diagnostics Inc is for a loss of 23 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Insight Molecular Diagnostics Inc is $4.25, about 38.2% above its last closing price of $2.63

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2025

-0.24

-0.24

-0.26

Missed

-9.9

Dec. 31 2025

-0.44

-0.43

-1.93

Missed

-351.6

Sep. 30 2024

-0.44

-0.44

-0.98

Missed

-124.8​

Jun. 30 2024

-0.55

-0.56

-0.36

Beat

35.6

​​Mar. 31 2024

-0.65

-0.67

-1.13

Missed

-69.1

Dec. 31 2023

-1.14

-2.12

Missed

-86.5​

Sep. 30 2023

-1.00

-1.01

-0.81

Beat

19.6

Jun. 30 2023

-0.68

-1.30

-1.07

Beat

17.7

This summary was machine generated August 8 at 21:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI